Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Articles published by Harrow Harrow to Participate in B. Riley Securities 23rd Annual Institutional Investor Conference on May 24, 2023 May 17, 2023 From Harrow Via Business Wire Tickers HROW Harrow to Launch FDA-Approved IHEEZO™ at the 2023 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting May 04, 2023 From Harrow Via Business Wire Tickers HROW Harrow Launches ILEVRO®, NEVANAC®, and MAXIDEX® in the U.S. May 02, 2023 From Harrow Via Business Wire Tickers HROW Harrow to Announce First Quarter 2023 Financial Results on May 11, 2023 April 27, 2023 From Harrow Via Business Wire Tickers HROW Harrow Announces New $100 Million Secured Credit Facility with Oaktree March 28, 2023 From Harrow Via Business Wire Tickers HROW Harrow Announces Fourth Quarter and Year-End 2022 Financial Results March 23, 2023 From Harrow Via Business Wire Tickers HROW Harrow Announces Transitional Pass-Through Reimbursement Status for IHEEZO™ (Chloroprocaine Hydrochloride Ophthalmic Gel) 3% March 13, 2023 From Harrow Via Business Wire Tickers HROW Harrow Announces Appointment of Mark Mannebach, Ph.D., R.Ph. as Head of Regulatory Affairs and Pharmacovigilance March 06, 2023 From Harrow Via Business Wire Tickers HROW Harrow to Announce Fourth Quarter 2022 Financial Results on March 23, 2023 March 02, 2023 From Harrow Via Business Wire Tickers HROW Harrow Launches Next-Generation Compounded Atropine Formulations February 15, 2023 From Harrow Via Business Wire Tickers HROW Harrow Announces Permanent, Product-Specific J-Code (J2403) for IHEEZO™ (Chloroprocaine Hydrochloride Ophthalmic Gel) 3% for Ocular Surface Anesthesia Effective April 1, 2023 February 02, 2023 From Harrow Via Business Wire Tickers HROW Harrow Closes Acquisition of U.S. Rights to ILEVRO®, NEVANAC®, VIGAMOX®, MAXIDEX®, and TRIESENCE® and Will Begin Receiving Net Profit Payments for Acquired Products January 23, 2023 From Harrow Via Business Wire Tickers HROW Harrow Prices $25 Million Offering December 14, 2022 From Harrow Via Business Wire Tickers HROW Harrow Enters into Agreement to Acquire Exclusive U.S. Rights to ILEVRO®, NEVANAC®, VIGAMOX®, MAXIDEX®, and TRIESENCE® December 14, 2022 From Harrow Via Business Wire Tickers HROW Harrow and iOR Partners Expand National Product Supply Agreement November 30, 2022 From Harrow Via Business Wire Tickers HROW Harrow Announces Third Quarter 2022 Financial Results November 14, 2022 From Harrow Via Business Wire Tickers HROW Harrow Launches Atropine.com November 10, 2022 From Harrow Via Business Wire Tickers HROW Harrow to Announce Third Quarter 2022 Financial Results on November 14, 2022 October 28, 2022 From Harrow Via Business Wire Tickers HROW Harrow Sells Non-Ophthalmic Compounding Business October 05, 2022 From Harrow Via Business Wire Tickers HROW ImprimisRx Launches Fortisite™ (Tobramycin 1.5% + Vancomycin 5%) Compounded Antibiotic Formulation September 29, 2022 From Harrow Via Business Wire Tickers HROW Harrow Announces U.S. FDA Approval of IHEEZO™ (Chloroprocaine Hydrochloride Ophthalmic Gel) 3% for Ocular Surface Anesthesia September 27, 2022 From Harrow Via Business Wire Tickers HROW Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.